GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » Net Change in Cash

RemeGen Co (SHSE:688331) Net Change in Cash : ¥33 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is RemeGen Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

RemeGen Co's Net Change in Cash for the six months ended in Dec. 2024 was ¥86 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was ¥33 Mil.


RemeGen Co Net Change in Cash Historical Data

The historical data trend for RemeGen Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Net Change in Cash Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial 2,733.98 -1,011.70 312.36 -1,342.63 32.98

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -520.78 -949.52 -393.11 -53.23 86.21

RemeGen Co Net Change in Cash Calculation

RemeGen Co's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

RemeGen Co's Net Change in Cash for the quarter that ended in Dec. 2024


Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ¥33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RemeGen Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

No Headlines